{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:24:36Z","timestamp":1793744676987,"version":"4.6.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071676"],"award-info":[{"award-number":["82071676"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.pnpbp.2021.110476","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:19:28Z","timestamp":1636975168000},"page":"110476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Antioxidant interventions in autism spectrum disorders: A meta-analysis"],"prefix":"10.1016","volume":"113","author":[{"given":"Yiying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2021.110476_bb0005","first-page":"492","article-title":"Psychometric characteristics of the aberrant behavior checklist","volume":"89","author":"Aman","year":"1985","journal-title":"Am. J. Ment. Defic."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0010","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1752-8062.2009.00152.x","article-title":"Meta-analysis: a brief introduction","volume":"2","author":"Andrel","year":"2009","journal-title":"Clin. Translat. Sci."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.21307\/ane-2017-025","article-title":"Immune dysfunction and neuroinflammation in autism spectrum disorder","volume":"76","author":"Bjorklund","year":"2016","journal-title":"Acta Neurobiol. Exp."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0020","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1007\/s12035-019-01742-2","article-title":"Oxidative stress in autism spectrum disorder","volume":"57","author":"Bj\u00f8rklund","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0025","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/(SICI)1097-4547(20000601)60:5<613::AID-JNR6>3.0.CO;2-8","article-title":"Nitric oxide synthase induction in astroglial cell cultures: effect on heat shock protein 70 synthesis and oxidant\/antioxidant balance","volume":"60","author":"Calabrese","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0030","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1089\/ars.2009.3074","article-title":"Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders","volume":"13","author":"Calabrese","year":"2010","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0035","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/jnr.23893","article-title":"Hormesis, cellular stress response, and redox homeostasis in autism spectrum disorders","volume":"94","author":"Calabrese","year":"2016","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004703-200002000-00002","article-title":"Reciprocal social behavior in children with and without pervasive developmental disorders","volume":"21","author":"Constantino","year":"2000","journal-title":"J. Develop. Behav. Pediat."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0045","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1025014929212","article-title":"Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised","volume":"33","author":"Constantino","year":"2003","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12979-015-0046-8","article-title":"Heat shock proteins and hormesis in the diagnosis and treatment of neurodegenerative diseases","volume":"12","author":"Dattilo","year":"2015","journal-title":"Immunity & Ageing\u202f: I & A."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0055","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0004867416652735","article-title":"A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder","volume":"51","author":"Dean","year":"2017","journal-title":"The Australian New Zealand J. Psychiatr."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0060","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neubiorev.2015.04.015","article-title":"Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review","volume":"55","author":"Deepmala","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0065","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical research ed)."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF02178498","article-title":"The developmental behavior checklist: the development and validation of an instrument to assess behavioral and emotional disturbance in children and adolescents with mental retardation","volume":"25","author":"Einfeld","year":"1995","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0075","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3218","article-title":"Dietary interventions for autism Spectrum disorder: a meta-analysis","volume":"144","author":"Fraguas","year":"2019","journal-title":"Pediatrics."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/mp.2016.168","article-title":"Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial","volume":"23","author":"Frye","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110476_bb0085","doi-asserted-by":"crossref","first-page":"792","DOI":"10.21037\/atm.2019.11.53","article-title":"Emerging biomarkers in autism spectrum disorder: a systematic review","volume":"7","author":"Frye","year":"2019","journal-title":"Annals Translat. Med."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0090","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnins.2016.00174","article-title":"Chemicals, nutrition, and autism spectrum disorder: a mini-review","volume":"10","author":"Fujiwara","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0095","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1474-4422(15)00044-7","article-title":"Gene hunting in autism spectrum disorder: on the path to precision medicine","volume":"14","author":"Geschwind","year":"2015","journal-title":"The Lancet Neurol."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0100","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1471-244X-13-196","article-title":"A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders","volume":"13","author":"Ghanizadeh","year":"2013","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0105","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/798957","article-title":"Ubiquinol improves symptoms in children with autism","volume":"2014","author":"Gvozdj\u00e1kov\u00e1","year":"2014","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0110","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A randomized controlled pilot trial of oral N-acetylcysteine in children with autism","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110476_bb0115","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10578-012-0292-3","article-title":"A double-blind placebo controlled trial of Ginkgo biloba added to risperidone in patients with autistic disorders","volume":"43","author":"Hasanzadeh","year":"2012","journal-title":"Child Psychiatry Hum. Dev."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0120","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/jcpt.13076","article-title":"Resveratrol as adjunctive therapy in treatment of irritability in children with autism: a double-blind and placebo-controlled randomized trial","volume":"45","author":"Hendouei","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0125","first-page":"1031","article-title":"Reduced amygdala-prefrontal functional connectivity in children with autism Spectrum disorder and co-occurring disruptive behavior","volume":"4","author":"Ibrahim","year":"2019","journal-title":"Biol. Psychiat. Cog. Neurosci. Neuroimag."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0130","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajmg.b.30366","article-title":"Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism","volume":"141b","author":"James","year":"2006","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0135","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1096\/fj.08-128926","article-title":"Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism","volume":"23","author":"James","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0140","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jpsychires.2018.04.022","article-title":"Palmitoylethanolamide as adjunctive therapy for autism: efficacy and safety results from a randomized controlled trial","volume":"103","author":"Khalaj","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ (Clinical research ed)."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0150","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1365-2788.2010.01359.x","article-title":"Is the autism treatment evaluation checklist a useful tool for monitoring progress in children with autism spectrum disorders?","volume":"55","author":"Magiati","year":"2011","journal-title":"J. Intellect. Dis. Res."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0155","series-title":"Alternative Therapies in Health and Medicine","first-page":"22","article-title":"Oxidative stress in autism","volume":"10","author":"McGinnis","year":"2004"},{"key":"10.1016\/j.pnpbp.2021.110476_bb0160","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1024\/1422-4917\/a000546","article-title":"Glutamatergic agents in the treatment of compulsivity and impulsivity in child and adolescent psychiatry: a systematic review of the literature","volume":"46","author":"Mechler","year":"2018","journal-title":"Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0165","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/jcpp.12382","article-title":"Irritability in boys with autism spectrum disorders: an investigation of physiological reactivity","volume":"56","author":"Mikita","year":"2015","journal-title":"J. Child Psychol. Psychiatry Allied Discip."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13229-017-0121-4","article-title":"Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses","volume":"8","author":"Modabbernia","year":"2017","journal-title":"Mol. Autism."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0175","doi-asserted-by":"crossref","first-page":"77001","DOI":"10.1289\/EHP8580","article-title":"Gene-environment interactions in developmental neurotoxicity: a case study of synergy between chlorpyrifos and CHD8 knockout in human BrainSpheres","volume":"129","author":"Modafferi","year":"2021","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0180","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/pcn.13016","article-title":"Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: a randomized, double-blind, placebo-controlled clinical trial","volume":"74","author":"Momtazmanesh","year":"2020","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/WNF.0000000000000063","article-title":"N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety","volume":"38","author":"Nikoo","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2020.137267","article-title":"Exposure of ultrafine particulate matter causes glutathione redox imbalance in the hippocampus: a neurometabolic susceptibility to Alzheimer\u2019s pathology","volume":"718","author":"Park","year":"2020","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0195","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1362361306064434","article-title":"Quantitative assessment of autistic symptomatology in preschoolers","volume":"10","author":"Pine","year":"2006","journal-title":"Autism"},{"key":"10.1016\/j.pnpbp.2021.110476_bb0200","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.psychres.2015.05.021","article-title":"Increased homocysteine levels correlate with the communication deficit in children with autism spectrum disorder","volume":"229","author":"Puig-Alcaraz","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/104012370902100404","article-title":"Novel and emerging treatments for autism spectrum disorders: a systematic review","volume":"21","author":"Rossignol","year":"2009","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2021.110476_bb0210","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1469-8749.2011.03980.x","article-title":"Melatonin in autism spectrum disorders: a systematic review and meta-analysis","volume":"53","author":"Rossignol","year":"2011","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/nu8060337","article-title":"Efficacy of folic acid supplementation in autistic children participating in structured teaching: an open-label trial","volume":"8","author":"Sun","year":"2016","journal-title":"Nutrients."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0220","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clinthera.2013.04.006","article-title":"An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders","volume":"35","author":"Taliou","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0225","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.tips.2008.06.002","article-title":"Novel therapeutic targets for autism","volume":"29","author":"Theoharides","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0230","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1517\/14656560903107789","article-title":"Autism: an emerging \u2018neuroimmune disorder\u2019 in search of therapy","volume":"10","author":"Theoharides","year":"2009","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0235","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-079X.2007.00528.x","article-title":"A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities","volume":"44","author":"Wasdell","year":"2008","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13229-016-0088-6","article-title":"A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder","volume":"7","author":"Wink","year":"2016","journal-title":"Mol. Autism."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0245","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10803-010-1036-5","article-title":"Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial","volume":"41","author":"Wright","year":"2011","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0250","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamapediatrics.2018.4208","article-title":"Prevalence and treatment patterns of autism spectrum disorder in the United States, 2016","volume":"173","author":"Xu","year":"2019","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.pnpbp.2021.110476_bb0255","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JCP.0b013e3182485791","article-title":"Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial","volume":"32","author":"Yui","year":"2012","journal-title":"J. Clin. Psychopharmacol."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584621002359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584621002359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:02:04Z","timestamp":1759521724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584621002359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":51,"alternative-id":["S0278584621002359"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110476","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antioxidant interventions in autism spectrum disorders: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2021.110476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110476"}}